4-acetyl-7-methoxy-2H-chromen-2-one | 118067-17-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 4-acetyl-7-methoxy-2H-chromen-2-one
• 英文别名: 7-methoxy-4-acetylcoumarin；2H-1-Benzopyran-2-one, 4-acetyl-7-methoxy-；4-acetyl-7-methoxychromen-2-one
• CAS: 118067-17-7
• 化学式: C₁₂H₁₀O₄
• 分子量: 218.209
• InChiKey: HRFAULWZGJAWAV-UHFFFAOYSA-N

物化性质

• 熔点：
  144-146 °C
• 沸点：
  423.9±45.0 °C(Predicted)
• 密度：
  1.281±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  苯甲醛 、 4-acetyl-7-methoxy-2H-chromen-2-one 在 哌啶 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 7-methoxy-4-(3-phenylprop-2-enoyl)chromen-2-one
  参考文献：
  名称：

  Synthesis and biological evaluation of novel coumarin-based inhibitors of Cdc25 phosphatases

  摘要：

  The cell division cycle 25 (Cdc25) family of proteins are dual specificity phosphatases that activate cyclin-dependent kinase (CDK) complexes, which in turn regulate progression through the cell division cycle. Overexpression of Cdc25 proteins has been reported in a wide variety of cancers; their inhibition may thus represent a novel approach for the development of anticancer therapeutics. Herein we report new coumarin-based scaffolds endowed with a selective inhibition against Cdc25A and Cdc25C, being 6a and 6d the most efficient inhibitors and worthy of further investigation as anticancer agents. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.130
• 作为产物：
  描述：

  4-乙基-7-羟基香豆素 在 selenium(IV) oxide 、 potassium carbonate 作用下， 以 丙酮 、 xylene 为溶剂， 反应 5.5h， 生成 4-acetyl-7-methoxy-2H-chromen-2-one
  参考文献：
  名称：

  Ito, Kiichi; Nakajima, Kaoru, Journal of Heterocyclic Chemistry, 1988, vol. 25, p. 511 - 515

  摘要：

  DOI：

文献信息

• Facile synthesis of 4-acetyl-coumarins, -thiocoumarin and -quinolin-2(1H)-one via very high α-regioselective Heck coupling on tosylates
  作者：Sergio Valente、Gilbert Kirsch

  DOI：10.1016/j.tetlet.2011.04.033

  日期：2011.7

  An efficient synthesis of a series of methyl ketones at the C4 position of coumarins, coumarin-containing heterocycles and analogous scaffolds is reported via very high α-regioselective Heck coupling using tosylates and in very high yields. Although α-regioselectivity in Heck coupling can be obtained with triflates as substrates, tosylates are less toxic, less expensive and, importantly, more stable

  据报道，通过使用甲苯磺酸盐的非常高的α-区域选择性Heck偶联，并以非常高的收率，在香豆素，含香豆素的杂环和类似支架的C4位有效合成了一系列甲基酮。尽管可以用三氟甲磺酸酯作为底物获得Heck偶联中的α-区域选择性，但是甲苯磺酸盐的毒性较小，价格较低并且重要的是更稳定。
• Caged tetracycline (derivatives), their generation, and their use for photoactivated gene expression
  申请人：Cambridge Sidney

  公开号：US20060105458A1

  公开（公告）日：2006-05-18

  Transcriptionally inactivated (caged) tetracycline or tetracycline derivative, wherein the inactivation is caused by reaction of the tetracycline (derivative) with a photosensitive protection compound, said caged tetracycline or tetracycline derivative being capable to be activated again by photolysis.

  转录失活（caged）四环素或四环素衍生物，其中失活是由四环素（衍生物）与光敏保护化合物反应引起的，所述caged四环素或四环素衍生物能够通过光解再次被激活。
• Inhibition of matrix metalloproteases by substitued biaryl oxobutyric acides
  申请人：——

  公开号：US20020042418A1

  公开（公告）日：2002-04-11

  Matrix metalloprotease inhibiting compounds, pharmaceutical compositions thereof and a method of disease treatment using such compounds are presented. The compounds of the invention have the generalized formulas: 1 wherein r is 0-2, T is selected from 2 and R 40 is a mono- or bi-heterocyclic structure. These compounds are useful for inhibiting matrix metalloproteases and, therefore, combating conditions to which MMP's contribute, such as osteoarthritis, rheumatoid arthritis, septic arthritis, periodontal disease, corneal ulceration, proteinuria, aneurysmal aortic disease, dystrophobic epidermolysis, bullosa, conditions leading to inflammatory responses, osteopenias mediated by MMP activity, tempero mandibular joint disease, demyelating diseases of the nervous system, tumor metastasis or degenerative cartilage loss following traumatic joint injury, and coronary thrombosis from athrosclerotic plaque rupture. The present invention also provides pharmaceutical compositions and methods for treating such conditions.

  本发明提供了抑制基质金属蛋白酶的化合物、其制药组合物以及使用这些化合物的疾病治疗方法。该发明的化合物具有以下通用式：其中r为0-2，T选自2，R40是单环或双环杂环结构。这些化合物有助于抑制基质金属蛋白酶，从而对抗MMP所贡献的疾病，如骨关节炎、类风湿性关节炎、化脓性关节炎、牙周病、角膜溃疡、蛋白尿、动脉瘤性主动脉疾病、营养不良性表皮松解性水疱病、导致炎症反应的疾病、MMP活性介导的骨质疏松、颞下颌关节疾病、神经系统脱髓鞘性疾病、肿瘤转移或创伤性关节损伤后的退行性软骨丢失以及由动脉粥样硬化斑块破裂引起的冠状动脉血栓形成。本发明还提供了治疗这些疾病的制药组合物和方法。
• Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids
  申请人：VanZandt C. Michael

  公开号：US20050267102A1

  公开（公告）日：2005-12-01

  Matrix metalloprotease inhibiting compounds, pharmaceutical compositions thereof and a method of disease treatment using such compounds are presented. The compounds of the invention have the generalized formulas: wherein r is 0-2, T is selected from and R 40 is a mono- or bi-heterocyclic structure. These compounds are useful for inhibiting matrix metalloproteases and, therefore, combating conditions to which MMP's contribute, such as osteoarthritis, rheumatoid arthritis, septic arthritis, periodontal disease, comeal ulceration, proteinuria, aneurysmal aortic disease, dystrophobic epidermolysis, bullosa, conditions leading to inflammatory responses, osteopenias mediated by MMP activity, tempero mandibularjoint disease, demyelating diseases of the nervous system, tumor metastasis or degenerative cartilage loss following traumatic joint injury, and coronary thrombosis from athrosclerotic plaque rupture. The present invention also provides pharmaceutical compositions and methods for treating such conditions.

  本发明提供了抑制基质金属蛋白酶的化合物、其制药组合物以及使用这些化合物的疾病治疗方法。本发明的化合物具有广义的公式：其中r为0-2，T为选择自以下组合中的一种：且R40为单环或双杂环结构。这些化合物对于抑制基质金属蛋白酶非常有用，因此可以用于对抗MMP所贡献的疾病，例如骨关节炎、类风湿性关节炎、败血性关节炎、牙周病、角膜溃疡、蛋白尿、动脉瘤性主动脉疾病、营养不良性表皮松解症、导致炎症反应的疾病、MMP活性介导的骨质疏松症、颞下颌关节疾病、神经系统的脱髓鞘疾病、肿瘤转移或创伤性关节损伤后的退化性软骨丢失以及由动脉粥样硬化斑块破裂引起的冠状动脉血栓形成。本发明还提供了用于治疗这些疾病的制药组合物和方法。
• Ligands for Aldoketoreductases
  申请人：Yee Dominic J.

  公开号：US20100048604A1

  公开（公告）日：2010-02-25

  The present invention relates to compounds useful for detecting the activity of human aldoketoreductase 1Cs, compounds useful for competitively inhibiting human aldoketoreductase 1Cs and compounds useful for treating human aldoketoreductase 1C-related cancers, as well as pharmaceutical compositions and methods of manufacture thereof.

  本发明涉及用于检测人类醛基酮还原酶1Cs活性的化合物，用于竞争性抑制人类醛基酮还原酶1Cs的化合物以及用于治疗人类醛基酮还原酶1C相关癌症的化合物，以及其制药组合物和制造方法。